Pan-Amyloid
Leading the Next Generation of Therapies
Amyl Therapeutics is a preclinical-stage biotechnology company developing Pan-Amyloid Immunotherapy, a groundbreaking approach designed to become a universal treatment for neurodegenerative diseases.
Neurodegenerative Diseases Affect Millions
Everyone knows someone impacted by Alzheimer’s, Parkinson’s, or another neurodegenerative disease. These diseases cause progressive decline in memory, mobility, emotions, and overall quality of life. Life expectancy is often shortened. Beyond the individual, these diseases take a profound emotional and financial toll on families and healthcare systems.
At Amyl Therapeutics, our vision is to develop THE treatment patients with Alzheimer’s and other neurodegenerative diseases urgently need. We are advancing a Pan-Amyloid Immunotherapy designed to:
Target all toxic amyloid species — including oligomers and fibrils — across neurodegenerative and systemic amyloid-mediated diseases, with superior efficacy compared to current therapies.
Act at every stage of disease progression — by both inhibiting the formation of early-stage aggregates and clearing mature fibrils, offering both preventative and curative potential.
Be engineered for optimal safety and delivery, with reduced risk of side effects and enhanced brain penetration to effectively reach its target and exert therapeutic benefit.